Provided By GlobeNewswire
Last update: Apr 29, 2025
– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer –
– TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health –
Read more at globenewswire.comNASDAQ:PROF (6/27/2025, 2:07:52 PM)
5.99
-0.16 (-2.6%)
Find more stocks in the Stock Screener